Vitamin D3 therapy corrects the tissue sensitivity to angiotensin II akin to the action of a converting enzyme inhibitor in obese hypertensives: An interventional study

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 7, 2012, Pages 2456-2465

  Vaidya, Anand ^a   Sun, Bei ^a   Larson, Carol ^a   Forman, John P ^a   Williams, Jonathan S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALDOSTERONE; ANGIOTENSIN II DERIVATIVE; CAPTOPRIL; COLECALCIFEROL; SODIUM; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ALDOSTERONE RELEASE; ARTICLE; DIET SUPPLEMENTATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; HYPERCALCEMIA; HYPERTENSION; INTERVENTION STUDY; KIDNEY BLOOD FLOW; MAJOR CLINICAL STUDY; MEAN ARTERIAL PRESSURE; OBESITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SENSITIVITY ANALYSIS; SODIUM BALANCE; TREATMENT DURATION; VITAMIN D DEFICIENCY; CLINICAL TRIAL; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; FEMALE; KIDNEY PLASMA FLOW; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CAPTOPRIL; CHOLECALCIFEROL; DRUG RESISTANCE; DRUG SYNERGISM; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OBESITY; RENAL PLASMA FLOW; VITAMIN D DEFICIENCY;

EID: 84863605896     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1156     Document Type: Article

References (48)

1. Hossain P, Kawar B, El Nahas M 2007 Obesity and diabetes in the developing world-a growing challenge. N Engl J Med 356:213-215 (Pubitemid 46143224)
2. Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, Moore SC, Tobias GS, Anton-Culver H, Freeman LB, Beeson WL, Clipp SL, English DR, Folsom AR, Freedman DM, Giles G, Hakansson N, Henderson KD, Hoffman-Bolton J, Hoppin JA, Koenig KL, Lee IM, Linet MS, Park Y, Pocobelli G, Schatzkin A, Sesso HD, Weiderpass E, Willcox BJ, Wolk A, Zeleniuch-Jacquotte A, Willett WC, Thun MJ 2010 Body-mass index and mortality among 1.46 million white adults. N Engl J Med 363:2211-2219
3. Engeli S, Negrel R, Sharma AM 2000 Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 35:1270-1277 (Pubitemid 30413663)
4. Engeli S, Schling P, Gorzelniak K, Boschmann M, Janke J, Ailhaud G, Teboul M, Massiéra F, Sharma AM 2003 The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 35:807-825 (Pubitemid 36379323)
5. Faloia E, Gatti C, Camilloni MA, Mariniello B, Sardu C, Garrapa GG, Mantero F, Giacchetti G 2002 Comparison of circulating and local adipose tissue renin-angiotensin system in normotensive and hypertensive obese subjects. J Endocrinol Invest 25:309-314 (Pubitemid 34436124)
6. Yvan-Charvet L, Quignard-Boulangé A 2011 Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int 79:162-168
7. Yasue S, Masuzaki H, Okada S, Ishii T, Kozuka C, Tanaka T, Fujikura J, Ebihara K, Hosoda K, Katsurada A, Ohashi N, Urushihara M, Kobori H, Morimoto N, Kawazoe T, Naitoh M, Okada M, Sakaue H, Suzuki S, Nakao K 2010 Adipose tissue-specific regulation of angiotensinogen in obese humans and mice: impact of nutritional status and adipocyte hypertrophy. Am J Hypertens 23:425-431
8. Vaidya A, Williams JS 2012 The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes. Metabolism 61:450-458
9. Vaidya A, Forman JP, Seely EW, Williams JS 2011 25-Hydroxyvitamin D is associated with plasma renin activity and the pressor response to dietary sodium intake in Caucasians. J Renin Angiotensin Aldosterone Syst 12:311-319
10. Vaidya A, Sun B, Forman JP, Hopkins PN, Brown NJ, Kolatkar NS, Williams GH, Williams JS 2011 The Vitamin D receptor gene polymorphism Fok1 is associated with plasma renin activity in Caucasians. Clin Endocrinol (Oxf) 74:783-790
11. Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm BO, März W 2010 Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system. The Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. Clin Chim Acta 411:1354-1360
12. Forman JP, Williams JS, Fisher ND 2010 Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension 55:1283-1288
13. Vaidya A, Forman JP, Williams JS 2011 Vitamin D and the vascular sensitivity to angiotensin II in obese Caucasians with hypertension. J Hum Hypertens 25:672-678
14. Beydoun MA, Boueiz A, Shroff MR, Beydoun HA, Wang Y, Zonderman AB 2010 Associations among 25-hydroxyvitamin D, diet quality, and metabolic disturbance differ by adiposity in United States adults. J Clin Endocrinol Metab 95:3814-3827
15. Snijder MB, van Dam RM, Visser M, Deeg DJ, Dekker JM, Bouter LM, Seidell JC, Lips P 2005 Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women. J Clin Endocrinol Metab 90:4119-4123 (Pubitemid 41058184)
16. Centers for Disease Control and Prevention 1996 The Third National Health and Nutrition Examination Survey (NHANES III 1988-94) reference manuals and reports [CD-ROM]. Bethesda, MD: National Center for Health Statistics
17. Dickinson BD, Havas S 2007 Reducing the population burden of cardiovascular disease by reducing sodium intake: a report of the Council on Science and Public Health. Arch Intern Med 167:1460-1468 (Pubitemid 47124176)
18. Fisher ND, Allan D, Kifor I, Gaboury CL, Williams GH, Moore TJ, Hollenberg NK 1994 Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans. Hypertension 23:44-51 (Pubitemid 24022043)
19. Shoback DM, Williams GH, Moore TJ, Dluhy RG, Podolsky S, Hollenberg NK 1983 Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension. J Clin Invest 72:2115-2124 (Pubitemid 14224417)
20. Redgrave J, Rabinowe S, Hollenberg NK, Williams GH 1985 Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition in essential hypertensives. J Clin Invest 75:1285-1290 (Pubitemid 15087158)
21. Chamarthi B, Williams JS, Williams GH 2010 A mechanism for salt-sensitive hypertension: abnormal dietary sodium-mediated vascular response to angiotensin-II. J Hypertens 28:1020-1026
22. Amir E, Simmons CE, Freedman OC, Dranitsaris G, Cole DE, Vieth R, Ooi WS, Clemons M 2010 A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D(3) in breast cancer patients with bone metastases. Cancer 116:284-291
23. Lee P, Greenfield JR, Seibel MJ, Eisman JA, Center JR 2009 Adequacy of vitamin D replacement in severe deficiency is dependent on body mass index. Am J Med 122:1056-1060
24. Przybelski R, Agrawal S, Krueger D, Engelke JA, Walbrun F, Binkley N 2008 Rapid correction of low vitamin D status in nursing home residents. Osteoporos Int 19:1621-1628
25. Wu F, Staykova T, Horne A, Clearwater J, Ames R, Mason B, Orr-Walker B, Gamble G, Scott M, Reid I 2003 Efficacy of an oral, 10-day course of high-dose calciferol in correcting vitamin D deficiency. N Z Med J 116:U536
26. Witham MD, Dove FJ, Dryburgh M, Sugden JA, Morris AD, Struthers AD 2010 The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia 53:2112-2119
27. Taylor T, Moore TJ, Hollenberg NK, Williams GH 1984 Converting-enzyme inhibition corrects the altered adrenal response to angiotensin II in essential hypertension. Hypertension 6:92-99 (Pubitemid 14187530)
28. Mallamaci F, Ruggenenti P, Perna A, Leonardis D, Tripepi R, Tripepi G, Remuzzi G, Zoccali C 2011 ACE inhibition is renoprotective among obese patients with proteinuria. J Am Soc Nephrol 22:1122-1128
29. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA 2011 The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96:53-58
30. Vaidya A, Forman JP 2010 Vitamin D and hypertension: current evidence and future directions. Hypertension 56:774-779
31. Forman JP, Curhan GC, Taylor EN 2008 Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension 52:828-832
32. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, Curhan GC 2007 Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 49:1063-1069 (Pubitemid 351664326)
33. Griffin FC, Gadegbeku CA, Sowers MR 2011 Vitamin D and subsequent systolic hypertension among women. Am J Hypertens 24:316-321
34. Deo R, Katz R, Shlipak MG, Sotoodehnia N, Psaty BM, Sarnak MJ, Fried LF, Chonchol M, de Boer IH, Enquobahrie D, Siscovick D, Kestenbaum B 2011 Vitamin D, parathyroid hormone, and sudden cardiac death: results from the cardiovascular health study. Hypertension 58:1021-1028
35. Vacek JL, Vanga SR, Good M, Lai SM, Lakkireddy D, Howard PA 2012 Vitamin D deficiency and supplementation and relation to cardiovascular health. Am J Cardiol 109:359-363
36. Margolis KL, Ray RM, Van Horn L, Manson JE, Allison MA, Black HR, Beresford SA, Connelly SA, Curb JD, Grimm Jr RH, Kotchen TA, Kuller LH, Wassertheil-Smoller S, Thomson CA, Torner JC 2008 Effect of calcium and vitamin D supplementation on blood pressure: the Women's Health Initiative Randomized Trial. Hypertension 52:847-855
37. Jorde R, Sneve M, Torjesen P, Figenschau Y 2010 No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J Intern Med 267:462-472
38. Avenell A, MacLennan GS, Jenkinson DJ, McPherson GC, Mc-Donald AM, Pant PR, Grant AM, Campbell MK, Anderson FH, Cooper C, Francis RM, Gillespie WJ, Robinson CM, Torgerson DJ, Wallace WA 2012 Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D3 and/or calcium (RECORD Trial). J Clin Endocrinol Metab 97:614-622
39. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP 2002 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the reninangiotensin system. J Clin Invest 110:229-238 (Pubitemid 34787360)
40. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D 2008 Calciumindependent and 1,25(OH)2D3-dependent regulation of the reninangiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 74:170-179 (Pubitemid 351915078)
41. Deb DK, Sun T, Wong KE, Zhang Z, Ning G, Zhang Y, Kong J, Shi H, Chang A, Li YC 2010 Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int 77:1000-1009
42. Ohara I, Tanimoto M, Gohda T, Yamazaki T, Hagiwara S, Murakoshi M, Aoki T, Toyoda H, Ishikawa Y, Funabiki K, Horikoshi S, Tomino Y 2011 Effect of combination therapy with angiotensin receptor blocker and 1,25-dihydroxyvitamin D3 in type 2 diabetic nephropathy in KK-Ay/Ta mice. Nephron Exp Nephrol 117:e124-e132
43. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC 2008 Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA 105:15896-15901
44. de Boer IH, Katz R, Chonchol M, Ix JH, Sarnak MJ, Shlipak MG, Siscovick DS, Kestenbaum B 2011 Serum 25-hydroxyvitamin d and change in estimated glomerular filtration rate. Clin J Am Soc Nephrol 6:2141-2149
45. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D 2010 Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376:1543-1551
46. Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO,März W 2010 Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J 31:1237-1247
47. Pilz S, Kienreich K, Drechsler C, Ritz E, Fahrleitner-Pammer A, Gaksch M, Meinitzer A, März W, Pieber TR, Tomaschitz A 2012 Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study. J Clin Endocrinol Metab 97:E75-E79
48. Atchison DK, Harding P, Beierwaltes WH 2011 Hypercalcemia reduces plasma renin via parathyroid hormone, renal interstitial calcium, and the calcium-sensing receptor. Hypertension 58:604-610